FDA Approves Gadavist (gadobutrol) Contrast Agent for Use in Cardiac MR in Adult Patients with Known or Suspected Coronary Artery Disease

WHIPPANY, N.J., July 15, 2019 /PRNewswire/ -- Bayer announced today the U.S. Food and Drug Administration (FDA) has approved Gadavist (gadobutrol) injection for use in cardiac magnetic resonance (MR) imaging to assess myocardial perfusion (stress,...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news